Tiopronin
Tiopronin (alpha-mercaptopropionylglycine) is a free thiol compound that forms mixed disulfide bonds with cysteine in urine, producing a more soluble cysteine-tiopronin complex that prevents cystine stone formation in patients with cystinuria by reducing free urinary cystine concentration below its saturation threshold. It is also used for the treatment of Wilson's disease as a copper-chelating agent and as a disease-modifying agent in rheumatoid arthritis. Its thiol group provides the chemical reactivity underlying all its clinical applications.
Khối lượng phân tử
163,2000 g/mol
LogP
-0,10
TPSA
67,40 Ų
Lipinski RO5
Đạt
Cơ chế tác dụng
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CC(S)C(=O)NCC(=O)O
InChI
InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)
Molecular Formula
C5H9NO3S
HBD / HBA
3 / 4
Liên kết có thể quay
3
Nguyên tử nặng
10
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
Tiopronin (alpha-mercaptopropionylglycine) is a free thiol compound that forms mixed disulfide bonds with cysteine in urine, producing a more soluble cysteine-tiopronin complex that prevents cystine stone formation in patients with cystinuria by reducing free urinary cystine concentration below its saturation threshold. It is also used for the treatment of Wilson's disease as a copper-chelating agent and as a disease-modifying agent in rheumatoid arthritis. Its thiol group provides the chemical reactivity underlying all its clinical applications.
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Yes, Tiopronin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1314. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5483. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tiopronin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tiopronin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tiopronin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tiopronin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tiopronin"></drugfyi-drug>